We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
TG Therapeutics (TGTX - Free Report) shares ended the last trading session 7.5% higher at $46.62. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2% gain over the past four weeks.
TG Therapeutics scored a strong price increase, on investors’ optimism driven by the recent announcement of positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis (MG). The company also initiated the Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG.
This biopharmaceutical company is expected to post quarterly earnings of $0.42 per share in its upcoming report, which represents a year-over-year change of +147.1%. Revenues are expected to be $230.64 million, up 63.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For TG Therapeutics, the consensus EPS estimate for the quarter has been revised 10.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TGTX going forward to see if this recent jump can turn into more strength down the road.
TG Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Nurix Therapeutics, Inc. (NRIX - Free Report) , closed the last trading session 2.2% lower at $15.3. Over the past month, NRIX has returned -2%.
For Nurix Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.73. This represents a change of -40.4% from what the company reported a year ago. Nurix Therapeutics currently has a Zacks Rank of #4 (Sell).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
TG Therapeutics (TGTX - Free Report) shares ended the last trading session 7.5% higher at $46.62. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2% gain over the past four weeks.
TG Therapeutics scored a strong price increase, on investors’ optimism driven by the recent announcement of positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis (MG). The company also initiated the Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG.
This biopharmaceutical company is expected to post quarterly earnings of $0.42 per share in its upcoming report, which represents a year-over-year change of +147.1%. Revenues are expected to be $230.64 million, up 63.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For TG Therapeutics, the consensus EPS estimate for the quarter has been revised 10.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TGTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
TG Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Nurix Therapeutics, Inc. (NRIX - Free Report) , closed the last trading session 2.2% lower at $15.3. Over the past month, NRIX has returned -2%.
For Nurix Therapeutics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.73. This represents a change of -40.4% from what the company reported a year ago. Nurix Therapeutics currently has a Zacks Rank of #4 (Sell).